Eli Lilly CEO Criticizes Germany's Planned Healthcare Reform as Terrible

US pharmaceutical giant Eli Lilly has expressed strong dissatisfaction with Germany. The company's CEO has openly criticized the country's planned healthcare reform. The executive described the proposed reforms as terrible in a recent statement. This indicates a significant conflict between the pharma major and the German government. The planned reforms represent a major shift in the nation's healthcare policy landscape. Eli Lilly's stance suggests the changes could negatively impact its business operations. The public criticism highlights the high stakes involved in the upcoming policy shifts. It remains to be seen how German officials will respond to the company's objections.